Key result
This review summarizes available evidence on the efficacy of new and conventional pharmacological agents for acute management, rhythm and rate control, and stroke prevention in atrial fibrillation.
Answers are grounded in this paper and cite their sources.
This review summarizes current pharmacological strategies for atrial fibrillation, highlighting the shift towards new antiarrhythmic and anticoagulant agents due to the limitations and toxicities of conventional drugs.
atrial fibrillation (AF) is associated with a significant burden of morbidity and increased risk of mortality. Antiarrhythmic drug therapy remains a cornerstone to restore and maintain sinus rhythm for patients with paroxysmal and persistent AF based on current guidelines. However, conventional drugs have limited efficacy, present problematic risks of proarrhythmia and cause significant noncardiac organ toxicity. Thus, inadequacies in current therapies for atrial fibrillation have made new drug development crucial. New antiarrhythmic drugs and new anticoagulant agents have changed the current management of AF. This paper summarizes the available evidence regarding the efficacy of medications used for acute management of AF, rhythm and ventricular rate control, and stroke prevention in patients with atrial fibrillation and focuses on the current pharmacological agents.
No takes yet. Share an insight, caveat, or question.
Lucà et al. (2011) conducted a review in Atrial fibrillation. Pharmacological agents (antiarrhythmic and anticoagulant drugs) was evaluated. This review summarizes available evidence on the efficacy of new and conventional pharmacological agents for acute management, rhythm and rate control, and stroke prevention in atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: